<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36990297</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2139</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain, behavior, and immunity</Title><ISOAbbreviation>Brain Behav Immun</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>229</EndPage><MedlinePgn>211-229</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbi.2023.03.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-1591(23)00079-X</ELocationID><Abstract><AbstractText>Empirical evidence addressing the association between SARS-CoV-2 vaccination and long COVID would guide public health priorities and inform personal health decisions. Herein, the co-primary objectives are to determine the differential risk of long COVID in vaccinated versus unvaccinated patients, and the trajectory of long COVID following vaccination. Of 2775 articles identified via systematic search, 17 were included, and 6 were meta-analyzed. Meta-analytic results determined that at least one vaccine dose was associated with a protective effect against long COVID (OR 0.539, 95% CI 0.295-0.987, p&#xa0;=&#xa0;0.045, N&#xa0;=&#xa0;257 817). Qualitative analysis revealed that trajectories of pre-existing long COVID following vaccination were mixed, with most patients reporting no changes. The evidence herein supports SARS-CoV-2 vaccination for the prevention of long COVID, and recommends long COVID patients adhere to standard SARS-CoV-2 vaccination schedules.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceban</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulzhabayeva</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Nelson B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Vincenzo</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Hartej</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniapillai</LastName><ForeName>Mehala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>Leanna M W</ForeName><Initials>LMW</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Roger C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 119077, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Taeho Greg</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblat</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Behav Immun</MedlineTA><NlmUniqueID>8800478</NlmUniqueID><ISSNLinking>0889-1591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410126">CI 987</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Brain Behav Immun. 2024 Jan;115:758. doi: 10.1016/j.bbi.2023.09.020</RefSource><PMID Version="1">37806865</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mood disorders</Keyword><Keyword MajorTopicYN="N">Population health</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19 PASC</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes,Neumora Therapeutics, Boehringer Ingelheim,Sage,Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, IntraCellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger S. McIntyre is a CEO of Braxia Scientific Corp. Dr. Roger Ho received funding from NUS Department of Psychological Medicine (R-177-000-100-001/R-177-000-003-001) and NUS iHeathtech Other Operating Expenses (R-722-000-004-731). Leanna M. W. Lui has received personal fees from Braxia Scientific Corp and honoraria from Medscape. Dr. Joshua D. Rosenblat is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Leanna Lui has received personal fees from Braxia Scientific Corp and honoraria Medscape.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36990297</ArticleId><ArticleId IdType="pmc">PMC10067136</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2023.03.022</ArticleId><ArticleId IdType="pii">S0889-1591(23)00079-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19. Research Square. 2021 doi: 10.21203/rs.3.rs-1062160/v1. published online Nov 15.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1062160/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun M.C., Singh A.K., Pal D., et al. Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19. bioRxiv. 2022 doi: 10.1101/2022.01.04.21268536. published online Jan 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.04.21268536</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. Ann Intern Med. 2021;174:1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Scott M.K.D., Hagan T., et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D., Bosworth, M. Self-reported long COVID after infection with the Omicron variant in the UK - Office for National Statistics. 2022; published online May 5. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022 (accessed May 15, 2022).</Citation></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B., et al. Changes in the trajectory of Long Covid symptoms following COVID-19 vaccination: community-based cohort study. bioRxiv. 2021 doi: 10.1101/2021.12.09.21267516. published online Dec 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.09.21267516</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bosworth M, King S. Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK. 2022; published online Jan 26. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/selfreportedlongcovidaftertwodosesofacoronaviruscovid19vaccineintheuk (accessed Feb 13, 2022).</Citation></Reference><Reference><Citation>Bach K. Is &#x2018;long Covid&#x2019; worsening the labor shortage? Brookings. 2022; published online Jan 11. https://www.brookings.edu/research/is-long-covid-worsening-the-labor-shortage/(accessed Feb 15, 2022).</Citation></Reference><Reference><Citation>Bergwerk M., Gonen T., Lustig Y., et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021;385:1474&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Better systematic review management. Covidence. 2020; published online June 11. https://www.covidence.org (accessed Feb 15, 2022).</Citation></Reference><Reference><Citation>Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: A systematic review and meta-analysis. JAMA Psychiatry 2021; published online July 28. DOI:10.1001/jamapsychiatry.2021.1818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319830</ArticleId><ArticleId IdType="pubmed">34319365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2021;101:93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Leber A., Jawad M.Y., et al. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect Dis. 2022:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="pubmed">35282780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia P.Y., Ong S.W.X., Chiew C.J., et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2021 doi: 10.1016/j.cmi.2021.11.010. published online Nov 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.010</ArticleId><ArticleId IdType="pmc">PMC8608661</ArticleId><ArticleId IdType="pubmed">34826623</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID19 vaccine tracker. https://covid19.trackvaccines.org (accessed Feb 7, 2022).</Citation></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021:374. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaber T.A.Z.K., Ashish A., Unsworth A., Martindale J. Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. British Journal of Medical Practitioners. 2021;14</Citation></Reference><Reference><Citation>Gupta R.K., Topol E.J. COVID-19 vaccine breakthrough infections. Science. 2021;374:1561&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">34941414</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman B, Viwattanakulvanid P, Dzulhadj A, Oo AC, Patricia K, Pongpanich S. Effect of full vaccination and post-covid olfactory dysfunction in recovered covid-19 patient. A retrospective longitudinal study with propensity matching. bioRxiv. 2022; published online Jan 11. DOI:10.1101/2022.01.10.22269007.</Citation></Reference><Reference><Citation>Kuodi, P., Gorelik, Y., Zayyad, H., et al., 2022. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv; 2022.01.05.22268800.</Citation></Reference><Reference><Citation>Latkin C.A., Dayton L., Yi G., Konstantopoulos A., Boodram B. Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective. Soc Sci Med. 2021;270</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834519</ArticleId><ArticleId IdType="pubmed">33485008</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald I., Murray S.M., Reynolds C.J., Altmann D.M., Boyton R.J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116645</ArticleId><ArticleId IdType="pubmed">33986272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra PK, Bruiners N, Ukey R, et al. Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells. medRxiv 2021; published online May 12. DOI:10.1101/2021.04.11.21255153.</Citation></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman DG D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090117</ArticleId><ArticleId IdType="pubmed">21603045</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O., Lui L.M.W., Eskander S., et al. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J Psychiatr Res. 2021;144:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovida F., Cassaniti I., Paolucci S., et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 2021;12:6032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521593</ArticleId><ArticleId IdType="pubmed">34654808</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Pijnenburg L., Chatelus E., et al. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines (Basel) 2021:10. doi: 10.3390/vaccines10010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010046</ArticleId><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. From online data collection to identification of disease mechanisms: The IL-1&#xdf;, IL-6 and TNF-&#x3b1; cytokine triad is associated with post-acute sequelae of COVID-19 in a digital research cohort. medRxiv 2021; : 2021.11.16.21266391.</Citation></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P, et al. Assessment of Post COVID-19 Health Problems and its Determinants in North India: A descriptive cross section study. medRxiv 2021; : 2021.10.03.21264490.</Citation></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R. Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. bioRxiv. 2021; published online Nov 18. DOI:10.1101/2021.11.17.21263608.</Citation></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00703-9. published online Dec 21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W.D., Sherwood O., Banerjee A., van der Togt V., Hishmeh L., Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID. Vaccines. 2022;10(5):652. doi: 10.2139/ssrn.3868856.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3868856</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 doi: 10.1016/j.cell.2022.01.014. published online Jan.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Zheng Q., Madhira V., et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2021;182:153&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. bioRxiv. 2021; published online Oct 26. DOI:10.1101/2021.10.26.21265508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France. 2021; published online Sept 29. DOI:10.2139/ssrn.3932953.</Citation></Reference><Reference><Citation>Wanga V., Chevinsky J.R., Dimitrov L.V., et al. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 &#x2014; United States, January 2020&#x2013;April 2021. MMWR. Morbidity and Mortality Weekly Report. 2021;70:1235&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao K., Gillissie E.S., Lui L.M.W., et al. Immune Response to Vaccination in Adults with Mental Disorders: A Systematic Review. J Affect Disord. 2022 doi: 10.1016/j.jad.2022.02.025. published online Feb 12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2022.02.025</ArticleId><ArticleId IdType="pmc">PMC8837484</ArticleId><ArticleId IdType="pubmed">35167926</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>